China WTO accession
This article was originally published in The Gray Sheet
Bilateral U.S.-Chinese agreement on China's accession to the World Trade Organization, announced Nov. 15, is expected to eliminate barriers hampering the medical technology industry's access to the Chinese market. Elimination of high tariffs, regulatory obstacles and distribution and import barriers is expected to make it possible for companies to provide basic medical care and technological innovations to the Chinese people, including development of health care insurance companies and hospitals. Both the Health Industry Manufacturers Association and Chindex International, Inc. applauded the agreement in releases Nov. 16 and 18 respectively. HIMA is participating in a Nov. 30 WTO ministerial conference in Seattle "in an accredited non-governmental advisory role"
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.